Connecticut’s Covid deaths have surpassed 8,000. We should take a moment to reflect on that and remember that a number is not just a number. Our case % remains around or below 3 % and people being becoming sick are trending younger and that’s good. Younger people do better in general, but not all.
This is one of the reason we encourage our members to file Worker’s Compensation Cases if they get Covid at work, even if they don’t miss income or incur medical bills. We are just discovering the long term effects, and you know how it goes, if it isn’t documented, it didn’t happen.
A study published in JAMA (study here, published in March; commentary here, published 4-20) is represented as one of the first of long-term COVID-19 sequelae.
The study reports that “Four months after hospitalization for COVID-19, a cohort of patients frequently reported symptoms not previously present, and lung-scan abnormalities were common among those who were tested.” The study, known as COMEBAC, (Consultation Multi-Expertise de Bicetre Apres COVID-19) “included adult patients admitted to the Bicetre Hospital (Paris-Saclay University hospitals) in France for COVID-19 from March 1 to May 29, 2020. Inclusion criteria were survival 4 months after hospital discharge or after intensive care unit (ICU) discharge for patients who had been admitted to an ICU . . . who had been hospitalized for greater than 24 hours primarily because of COVID-19, and who had received a diagnosis of SARS-CoV-2 infection by reverse transcriptase–polymerase chain reaction (RT-PCR), by typical computed tomographic (CT) lung scan associated with clinical features, or both.”
The commentary notes that “As of early March 2021, more than 2.5 million individuals worldwide have died from COVID-19, but many more millions have survived COVID-19 and experienced lasting sequelae. As many as half of patients who survive hospitalization for COVID-19 experience prolonged work absence, financial difficulty, or emotional effects, each of which
may further impede recovery.”
The commentary explains, “The term ‘long COVID,’ coined by patients early in the pandemic, has helped to raise awareness of the life-altering effects of COVID for many patients and to drive government action . . . Although potential sequelae of COVID-19 have been widely reported in news media, smaller case series, and convenience samples, this study is among the first to systematically and comprehensively evaluate the medical outcomes of hospital survivors,” and concludes that “The heterogeneity of symptom profiles suggests that a single approach to follow-up and management of long COVID will not be effective.”
Under “why do people rob banks? Because that’s where the money is.” The money my friends is now in healthcare.
18 highest-paid CEOs in healthcare
The CEOs of Centene, HCA Healthcare and AbbVie are among the highest-paid chief executives of the largest U.S. companies, according to Equilar.
For its ranking of the 100 highest-paid CEOs in 2020, Equilar examined proxy statements filed by companies before March 31.
The study showed that median CEO compensation was $15.5 million in 2020, down 1.6 percent from $15.7 million in its 2019 study. In line with the decline in median total compensation, 32 CEOs of the largest U.S. companies saw a smaller pay package in 2020 than a year earlier. Twenty-three CEOs saw compensation dip in 2019, according to the report.
Here are the 18 healthcare CEOs that made the highest paid list, in order of total compensation in 2020.
1. Michael Neidorff (Centene) — $24.96 million
2. Alex Gorsky (Johnson & Johnson) — $23.14 million
3. Richard A. Gonzalez (AbbVie) — $21.78 million
4. David M. Cordani (Cigna) — $19.74 million
5. Albert Bourla (Pfizer) — $19.67 million
6. Giovanni Caforio (Bristol-Myers Squibb) — $19.56 million
7. Daniel O'Day (Gilead Sciences) — $18.99 million
8. Samuel Hazen (HCA Healthcare) — $18.13 million
9. David Ricks (Eli Lilly) — $17.82 million
10. Joseph Zubretsky (Molina Healthcare) — $17.81 million
11. Stefano Penssina (Walgreens Boots Alliance) — $17.48 million
12. Bruce Broussard (Humana) — $16.49 million
13. Robert Ford (Abbott Laboratories) — $16.3 million
14. Steven Collis (AmerisourceBergen) — $14.3 million
15. Michael Kaufmann (Cardinal Health) — $14.22 million
16. Michael Hsu (Kimberly-Clark) — $13.47 million
17. Michael Roman (3M) — $12.99 million
18. Rainer Blair (Danaher) — $10.4 million
No comments:
Post a Comment